KPV

KPV (also known as Lysine-Proline-Valine, α-MSH (11-13), Alpha-MSH tripeptide) is a recovery research peptide. Three amino acids clipped from the tail of α-MSH — small enough to ride the PepT1 transporter directly into intestinal cells, where it shuts down NF-κB signalling.

KPV is the C-terminal tripeptide (residues 11–13) of α-melanocyte stimulating hormone, retaining the anti-inflammatory activity of the parent hormone while shedding its melanocortin receptor-mediated pigmentation effects. Its size is its defining property: at three residues it is unusually stable against proteolysis and is a substrate for PepT1, the intestinal di/tripeptide transporter, allowing it to be taken up directly into epithelial cells rather than acting from the lumen. Inside the cell it inhibits NF-κB nuclear translocation and MAPK signalling, suppressing production of TNF-α, IL-6 and IL-1β. The foundational evidence is a 2008 Gastroenterology paper showing orally administered KPV reduced inflammation in two mouse colitis models in a PepT1-dependent manner, plus a body of work on α-MSH peptides in intestinal barrier protection, wound healing and antimicrobial activity (α-MSH derivatives have direct activity against Candida albicans and Staphylococcus aureus). More recent work has examined KPV in hepatic lipid accumulation, keratinocyte protection against particulate damage, and nanocarrier formulations. What does not exist is human clinical trial data: no completed randomised trial has tested KPV as a single-agent drug.

1 Mechanism of action

Enters cells via the PepT1 di/tripeptide transporter (highly expressed in inflamed intestinal epithelium and in immune cells). Inhibits NF-κB nuclear translocation and MAPK pathway activation, reducing transcription of TNF-α, IL-6, IL-1β and other pro-inflammatory mediators. Retains α-MSH anti-inflammatory activity without MC1R-mediated melanogenesis.

Primary targets: PepT1 transporter (uptake) · NF-κB / MAPK signalling (intracellular targets)

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Reported benefits

• Reduced colitis severity in two independent murine models (oral dosing)
• Inhibits NF-κB and MAPK inflammatory signalling directly inside cells
• Retains α-MSH anti-inflammatory activity without pigmentation effects
• Exceptional proteolytic stability for a peptide
• Antimicrobial activity reported for α-MSH-derived peptides against Candida and S. aureus
• Investigated topically for dermatitis and wound healing

2.2 Side effects

• No human safety data — adverse effect profile essentially uncharacterised
• Injection site reactions reported anecdotally
• Theoretical immunosuppression with sustained NF-κB inhibition
• Possible reduced host response to infection with chronic use

3 Chemical and physical properties

3.1 Amino acid sequence

4 Research dosages

No validated human protocol. Rodent colitis studies used low microgram-per-kilogram oral doses; research protocols commonly cite 200–500 μg/day SC or oral, without supporting trial data.

5 Research studies (7)

1. The Tripeptide KPV Reduces Intestinal Inflammation via PepT1-Mediated Uptake
   Gastroenterology (2008) · Preclinical · N/A (murine)
   Oral KPV in DSS- and TNBS-induced murine colitis models, with PepT1 dependence demonstrated.
   Key finding: Oral KPV at low doses reduced colitis severity through PepT1-mediated epithelial uptake and NF-κB inhibition.
2. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.
   Science advances (2026) · Preclinical
   Oral delivery of peptide therapeutics remains challenging due to gastrointestinal (GI) degradation and poor intestinal absorption.
3. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.
   Cytotechnology (2026) · Preclinical
   Hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum, is characterized by excessive lipid accumulation and oxidative stress in hepatocytes.
4. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.
   Tissue & cell (2025) · Preclinical
   Airborne particulate matter (PM) poses a major environmental risk that impairs skin health by triggering oxidative stress, inflammation, and cell death.
5. KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
   Advanced healthcare materials (2024) · Preclinical
   Cardiovascular disease (CVD) is a leading cause of death globally, and vascular calcification (VC) is an important independent risk factor for predicting CVD.
6. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
   Journal of pharmaceutical sciences (2017) · Preclinical
   Lysine-proline-valine (KPV) is a C-terminal peptide fragment of α-melanocyte stimulating hormone with potent anti-inflammatory properties.
7. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.
   Biomedical chromatography : BMC (2015) · Preclinical
   A simple, sensitive and stability-indicating high-performance liquid chromatographic (HPLC) assay method was developed and validated for a bioactive peptide, lysine-proline-valine (KPV) in aqueous solutions...

6 Safety and risk profile

6.1 Regulatory status

KPV is currently classified as Not approved. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety score: 70/100 — low concern. Derived from clinical data volume, known risks and regulatory status.

6.2 Contraindications

Conditions and populations in which use is contraindicated:

• Active systemic infection (theoretical — NF-κB inhibition blunts host defence)
• Pregnancy or lactation
• Immunosuppressed states
• Known hypersensitivity to melanocortin fragments

6.3 Drug interactions

6.4 Long-term risks

• No long-term data of any kind in humans
• Chronic inhibition of NF-κB may impair immune surveillance
• Unknown effects on wound healing and tissue remodelling with prolonged use

6.5 Research best practices

• Store lyophilised at −20 °C, desiccated
• Reconstitute with bacteriostatic water; refrigerate and use within weeks
• Small peptides adsorb to surfaces — use low-binding plasticware for accurate dosing
• Treat all dosing figures as extrapolation, not established protocol

7 Frequently asked questions

Does KPV cause tanning like other melanocortin peptides?

No. Pigmentation is driven by MC1R activation, which requires the core melanocortin message sequence (His-Phe-Arg-Trp) found in full-length α-MSH. KPV is the C-terminal fragment and lacks it — which is precisely the point of using the fragment rather than the whole hormone.

Can KPV be taken orally?

The rodent colitis work used oral administration and depended on PepT1-mediated uptake by intestinal cells, so oral delivery is mechanistically coherent for gut-targeted effects. Systemic effects from oral dosing are far less established, and no human pharmacokinetic data exists.

What is the actual strength of evidence?

Preclinical only. There are cell and rodent studies across colitis, dermatitis, wound healing and antimicrobial models, but no completed human randomised trial of KPV as a single agent. Its US compounding status has shifted more than once and is not settled.

8 References

1. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. PubMed (2026). Cheng J, et al.. View source
2. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. PubMed (2026). Lee JY, et al.. View source
3. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. PubMed (2025). Sung J, et al.. View source
4. KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. PubMed (2024). Zhang L, et al.. View source

9 See also

• Peptide encyclopedia index
• Peptide reconstitution calculator
• Glossary of peptide research terms